文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重组人血小板生成素在脓毒症相关血小板减少危重患者中的作用:一项临床研究

[The role of recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: a clinical study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论脓毒症相关血小板减少患者加用rhTPO 15 000 U每日一次×7天可提高第5、7天血小板计数并减少血小板输注量,但不缩短ICU住院时间、总住院时间,不降低28天死亡率。

结果显示rhTPO组第5天和第7天血小板计数显著高于对照组(第5天63.94±44.01 vs 49.85±29.26×10⁹/L,第7天125.85±112.31 vs 76.81±50.87×10⁹/L,均P<0.05),血小板输注量更少[0(0,0)vs 0(0,2.00),P=0.001];但两组机械通气时间、ICU住院时间、总住院时间、总住院费用及28天结局差异均无统计学意义(均P>0.05)。凝血功能、心肌酶、肝肾功能及炎症指标在各时间点两组间均无显著差异。

要点

  • 脓毒症相关血小板减少患者在Sepsis-3指南治疗基础上加用rhTPO 15 000 U每日一次×7天,第5、7天血小板计数显著高于对照组(均P<0.05)。
  • rhTPO组血小板输注量低于对照组[0(0,0)vs 0(0,2.00),P=0.001],可减少血小板制品输注。
  • rhTPO未缩短机械通气时间、ICU住院时间及总住院时间,也未降低28天死亡率(均P>0.05)。
  • rhTPO组与对照组在凝血功能(PT、PTA)、心肌酶(Tn、CK)、肝肾功能(AST、TBil、Cr)及炎症指标(PCT、CRP)各时间点均无显著差异(均P>0.05)。
  • TPO组内按基线PLT<50×10⁹/L(34例)与≥50×10⁹/L(16例)分层,血小板上升绝对值、机械通气时间、ICU住院时间、总住院时间及28天结局差异均无统计学意义(均P>0.05)。

适用人群与场景

  • 两组均按Sepsis-3指南治疗;原文未提及具体排除标准。

诊断标准与关键阈值

  • 原文未提及脓毒症相关血小板减少的具体诊断界值;仅以血小板计数<50×10⁹/L将TPO组分为TPO B组(34例),≥50×10⁹/L为TPO A组(16例)。

处置流程与药物剂量

  • 第一步:两组均按Sepsis-3指南进行基础治疗。
  • 第二步:TPO组在基础治疗上加用rhTPO 15 000 U,每日一次,疗程7天;对照组仅常规治疗。
  • 第三步:治疗前及治疗后第1、3、5、7天监测血小板计数、凝血功能(PT、PTA)、心肌酶(Tn、CK)、肝肾功能(AST、TBil、Cr)及炎症指标(PCT、CRP)。
  • 第四步:记录血制品输注量、机械通气时间、ICU住院时间、总住院时间、总住院费用及28天结局。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预与对照:TPO组(50例)在Sepsis-3指南治疗基础上加rhTPO 15 000 U每日一次×7天,对照组(50例)仅按指南治疗。
  • 主要血小板结果:TPO组第5天PLT显著高于对照组(63.94±44.01 vs 49.85±29.26×10⁹/L,P<0.05),第7天亦显著高于对照组(125.85±112.31 vs 76.81±50.87×10⁹/L,P<0.05)。
  • 血小板输注量:TPO组低于对照组[0(0,0)vs 0(0,2.00),P=0.001]。
  • 其他终点:机械通气时间、ICU住院时间、总住院时间、总住院费用及28天结局两组差异均无统计学意义(均P>0.05);PT、PTA、Tn、CK、AST、TBil、Cr、PCT、CRP各时间点两组间均无显著差异(均P>0.05)。
  • TPO组内分层:TPO A组(PLT≥50×10⁹/L,16例)机械通气时间、ICU住院时间、总住院时间及血小板上升绝对值与TPO B组(PLT<50×10⁹/L,34例)比较差异均无统计学意义(均P>0.05)。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照研究(单中心)。

对床旁实践的改变

  • 对脓毒症相关血小板减少患者,在Sepsis-3指南治疗基础上可考虑加用rhTPO 15 000 U每日一次×7天以提升血小板计数并减少血小板输注量。
  • 不应期望rhTPO缩短机械通气时间、ICU住院时间或总住院时间,也不应期望其降低28天死亡率。
  • 原文未提及rhTPO的适用与不适用人群筛选标准,临床决策需结合原文未覆盖的个体情况。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effect of recombinant human thrombogenin (rhTPO) on sepsis-associated thrombocytopenia.

METHODS: A prospective randomized controlled study was conducted. One hundred patients with sepsis-associated thrombocytopenia admitted to the department of critical care medicine of the First Affiliated Hospital of Zhengzhou University from August 2019 to October 2020 were enrolled. The enrolled patients were divided into rhTPO-using group (TPO group) and routine group (control group) by random number table method, with 50 cases in each group. Both groups were treated according to the guideline of Sepsis-3. In addition, TPO group received rhTPO 15 000 U, once daily for 7 days. Geneal information and acute physiology and chronic health evaluation II (APACHE II) were recorded. The levels of platelet count (PLT), blood coagulation function [prothrombin time (PT) and prothrombin activity (PTA)], myocardial enzyme indexes [troponin (Tn) and creatine kinase (CK)], liver and kidney function [aspartate aminotransferase (AST), total bilirubin (TBil) and creatinine (Cr)] and inflammatory biomarkers [procalcitonin (PCT) and C-reactive protein (CRP)] were recorded before treatment and 1, 3, 5 and 7 days after treatment. The infusion volume of blood components, duration of mechanical ventilation, length of stay in ICU, total length of hospitalization, total cost of hospitalization and 28-day outcome were recorded. According to whether the PLT was lower than 50×109/L, the patients in TPO group were divided into the TPO A group (PLT ≥ 50×109/L, 16 cases) and TPO B group (PLT < 50×109/L, 34 cases), and the absolute value of PLT increase, duration of mechanical ventilation, length of stay in ICU, total length of hospitalization, total cost of hospitalization and 28-day outcome of the two groups were compared.

RESULTS: (1) In TPO and control groups, there were no statistically significant differences in gender, age, proportion of patients with primary infection site, APACHEII score, PLT, coagulation function, myocardial enzymes, liver and kidney function and inflammation indexes before treatment (all P > 0.05). (2) The PLT levels of the TPO group were significantly higher than those of the control group on the 5th and 7th day after treatment (×109/L: day 5, 63.94±44.01 vs. 49.85±29.26, day 7, 125.85±112.31 vs. 76.81±50.87, both P < 0.05), and there were no statistically significant differences in PT, PTA, Tn, CK, AST, TBil, Cr, PCT or CRP before and on the 1, 3, 5, 7 days after treatment between TPO and control groups (all P > 0.05). (3) The amount of platelet transfusion in the TPO group was lower than that in the control group [treatment amount: 0 (0, 0) vs 0 (0, 2.00), P = 0.001]. (4) There were no statistically significant differences in mechanical ventilation time, length of stay in ICU, total length of hospitalization, total cost of hospitalization or 28-day outcome between TPO and control groups (all P > 0.05). The mechanical ventilation time, ICU stay time and total hospitalization time of TPO A group were longer than those in TPO B group, but the differences were not statistically significant [mechanical ventilation time (hours): 131.00 (0, 311.00) vs. 50.00 (0, 192.00), ICU stay time (days): 14.44±8.57 vs. 11.73±9.24, total hospitalization time (days): 15.00 (6.00, 23.50) vs. 18.00 (8.00, 31.00), all P > 0.05]. The absolute value of PLT increase in TPO A group was higher than that of TPO B group, but the difference was not statistically significant [×109/L: 65.00 (16.50, 131.50) vs. 36.00 (18.00, 130.00), P > 0.05].

CONCLUSIONS: RhTPO can significantly increase the PLT of patients with sepsis-related thrombocytopenia, thereby reduce the amount of platelet transfusion, but it cannot shorten the length of ICU stay time and total hospitalization time, and it cannot reduce 28-day mortality.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Dong F, Ma N, Chang S, et al. [The role of recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: a clinical study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33541495. doi:10.3760/cma.j.cn121430-20201130-00737

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。